Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085548 | 1.00 | PLAT (0.34) | PLATCSNK2A2CSNK2BCSNK2A1KDM4E | |
| SCHEMBL2085798 | 0.77 | KDM4E (0.39) | KDM4EBRAF | |
| SCHEMBL2085633 | 0.73 | CSNK2A2 (0.33) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL4640091 | 0.68 | CSNK2A2 (0.33) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL3210973 | 0.64 | RXFP1 (0.36) | CSNK2A2CSNK2BCSNK2A1BRAF | |
| SCHEMBL13015484 | 0.61 | ADORA3 (0.45) | KDM4EALDH1A1 | |
| SCHEMBL31122027 | 0.61 | ADORA3 (0.45) | KDM4EALDH1A1 | |
| SCHEMBL3205341 | 0.58 | KMT2A (0.39) | CSNK2A2CSNK2BCSNK2A1ALDH1A1 | |
| SCHEMBL2084597 | 0.56 | PDE3B (0.36) | — | |
| SCHEMBL2084601 | 0.56 | PDE3B (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163935-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090312383-A1 | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-1874736-A4 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1874736-A2 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006116412-A2 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312383-A1 | Fused Heterocyclic Compounds | NPY4R, CRHR1, CNR1 | PLAT 4627/4885CSNK2A2 731/4885CSNK2B 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.